<DOC>
	<DOCNO>NCT00005028</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine paclitaxel bryostatin 1 treating patient metastatic prostate cancer respond hormone therapy . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Paclitaxel Bryostatin 1 Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine onset , duration , degree response patient hormone-refractory , metastatic adenocarcinoma prostate treat paclitaxel bryostatin 1 . II . Determine toxicity regimen patient . III . Determine overall survival patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 bryostatin 1 IV 1 hour day 2 , 9 , 16 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Patients follow monthly 6 month every 3 month thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma prostate fail first secondline hormonal therapy ( e.g. , gonadal androgen suppression [ orchiectomy luteinizing hormonereleasing hormone ] without antiandrogens ) Failure hormonal therapy define 1 follow criterion : Biochemical progression ( withdrawal antiandrogens ) , document 3 rise PSA value , value measure least 2 week apart , last measurement least 25 % nadir achieve hormonal therapy increase absolute value least 5 ng/mL Measurable disease progression , define increase sum product perpendicular diameter measurable lesion ( ) least 25 % Bone progression allow concurrent biochemical progression Castrate level testosterone ( great 50 ng/dL ) No clinical signs/symptoms suggest CNS metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 6 month Hematopoietic WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal Creatinine great 1.5 time ULN Calcium great ULN Cardiovascular No uncontrolled severe cardiovascular disease No myocardial infarction within past 6 month No congestive heart failure No angina pectoris No active thromboembolic event within past 3 month ( e.g. , deep venous thrombosis cerebrovascular accident ) Other No serious medical psychiatric illness No active infection No dementia significantly alter mental status No prior concurrent grade 1 great peripheral neuropathy No prior concurrent malignancy within past 5 year except curatively treat nonmelanoma skin cancer HIV negative Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Chemotherapy No prior chemotherapy ( include paclitaxel ) Endocrine therapy At least 4 week since prior steroid megestrol Radiotherapy At least 4 week since prior radiotherapy bone lesions Other No concurrent investigational therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>